The global pen needles market size is estimated to reach USD 7.8 billion by 2030, registering a CAGR of 10.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of diabetes is the primary reason for the significant growth of the pen needles market. According to the National Library of Medicine, the number of people with diabetes is expected to climb by 1.51 million in 2023, owing primarily to the ageing population. Such high prevalence of diabetes across the globe has led to rising demand for pen needles. Patients suffering from diabetes commonly use injectable pen devices, which help in easy drug delivery.
In addition, obesity is a significant cause of diabetes. Obese people often suffer from type 2 diabetes, which makes them one of the highest revenue contributors to the target market. Thus, people with type 2 diabetes are the common target population for companies manufacturing pen needles.
Rising technological advancements is also expected to drive the market growth. Pen needles allow comfort and easy mode of insulin delivery. These devices are technologically advanced and provide a superior alternative drug delivery method in comparison to syringes and vials. For instance, Becton, Dickinson, and Company launched BD Ultra-Fine Nano 4mm Pen Needles with Easy Flow Technology, which will enable diabetic patients with easy adherence to insulin therapy regimens.
Request a free sample copy or view report summary: Pen Needles Market Report
By product, the standard segment dominated the market in 2024, due to the availability of cost-effective needles as compared to safety needles.
Safety pen needles are anticipated to showcase lucrative growth over the forecast period due to the continuous technological advancements.
Amongst the needle lengths, 5 mm-sized pen needles segment held the largest share in 2024, due to its optimal balance of comfort and effectiveness for subcutaneous injections.
Needle length of 4mm are expected to witness attractive CAGR over the forecast period owing to its short length.
Insulin therapy accounted for the largest market share in 2024, due to rising awareness regarding self-administration of insulin amongst the diabetic patients.
Europe dominated the pen needles market in 2024, followed by North America owing to the high prevalence of diabetes in the European region.
Asia Pacific region is anticipated to exhibit the significant CAGR over the forecast period, owing to the rising awareness levels amongst the diabetic population regarding easy drug delivery.
Grand View Research has segmented the global pen needles market on the basis of product, needle length, therapy, and region:
Pen Needles Product Outlook (Revenue, USD Million, 2018 - 2030)
Standard Pen Needles
Safety Pen Needles
Pen Needles Needle Length Outlook (Revenue, USD Million, 2018 - 2030)
4mm
5mm
6mm
8mm
10mm
12mm
Pen Needles Therapy Outlook (Revenue, USD Million, 2018 - 2030)
Insulin
Glucagon-like-peptide-1
Growth Hormone
Pen Needles Region Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Pen Needles Market
Novo Nordisk A/S
Becton Dickinson and Company
Terumo Corp.
Owen Mumford Ltd.
Ypsomed
B. Braun Melsungen AG
HTL-STREFA
UltiMed, Inc.
Allison Medical, Inc.
Artsana S.p.A.
"The quality of research they have done for us has been excellent..."